Clinical development and current role of margetuximab for the treatment of breast cancer

• P. Tarantino ^[2] ; J. Uliano ^[2] ; S. Morganti ^[2] ; F. Giugliano ^[2] ; E. Crimini ^[2] ; G. Curigliano ^{[2] [1]}
  1. [1] University of Milan

     University of Milan

     Milán, Italia

     
  2. [2] Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 57, Nº. 9, 2021, págs. 551-558
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Up to 20% of breast cancers overexpress HER2, a molecular alteration conferring these tumors a particularly aggressive behavior. However, targeting HER2 has radically changed the prognosis of this disease in the last 2 decades, with multiple anti-HER2 compounds shown to improve disease outcomes both in the early and advanced setting. The latest anti-HER2 compound to be approved by the U.S. Food and Drug Administration (FDA) was margetuximab, an Fc-engineered monoclonal antibody with an improved binding to FcgammaRIIIA receptor, which leads to a greater antibody-dependent cellular cytotoxicity (ADCC) activation compared with trastuzumab. Margetuximab was shown to slightly improve progression-free survival compared with trastuzumab when combined with chemotherapy for the treatment of advanced HER2-positive breast cancer patients, and is now included among the available treatment options for pretreated HER2-positive breast cancer patients. In this monograph we recapitulate the clinical development, current role and future perspectives of margetuximab for the treatment of breast cancer.